Sermorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH) that is commonly used to evaluate and enhance endogenous growth hormone production. Research interest in sermorelin stems from its potential roles in promoting bone density, minimizing scar formation, mitigating cognitive decline associated with dementia, and reducing seizure occurrence.

BPC-157 is a peptide made up of 15 amino acids, originally discovered in human gastric juice. Research shows that it supports faster healing of muscles, tendons, ligaments, and even skin injuries such as burns. It also helps protect organs and may prevent gastric ulcers. In the digestive system, BPC-157 has been shown to support gut health by helping with issues like leaky gut, IBS, cramps, and Crohn’s disease. In addition, it may reduce pain and speed up recovery by improving blood flow, boosting collagen production, and supporting new tissue and blood vessel growth. Because of these benefits, BPC-157 is being studied as a promising option for wound healing and overall recovery support.

GHK-Cu is an endogenous peptide naturally present in human plasma, urine, and saliva. Preclinical studies in animal models indicate that GHK-Cu enhances wound repair, supports immune function, and promotes skin regeneration by stimulating collagen synthesis, activating fibroblasts, and facilitating angiogenesis. Evidence also suggests that it functions as a feedback signal released following tissue injury. Additionally, GHK-Cu exhibits antioxidant properties by mitigating free radical–induced damage.

Cagrilintide is a long-acting analogue of amylin, a natural peptide released alongside insulin. In animal studies, it has shown potential for treating obesity and type 2 diabetes. Beyond these uses, research has explored its possible benefits for liver injury, alcohol-related liver disease, and cardiovascular conditions. There is also speculation about its role in Alzheimer’s disease, though no studies have yet been published in that area. Several trials have examined cagrilintide in combination with semaglutide for obesity and type 2 diabetes, with evidence suggesting the two agents may act synergistically to promote greater and more sustained weight loss. While preclinical findings are encouraging, clinical data in humans remain limited, and further studies are needed to fully establish its efficacy and safety.

Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide and ubiquitous coenzyme present in all living cells, where it plays a central role in cellular metabolism and bioenergetics. Acting as a redox mediator, NAD+ undergoes continuous interconversion between its oxidized (NAD+) and reduced (NADH) states, thereby facilitating electron transfer reactions fundamental to oxidative phosphorylation and ATP production. Beyond its canonical role in energy metabolism, NAD+ serves as a critical co-substrate in more than 500 enzymatic reactions, underscoring its broad involvement in cellular homeostasis. Accumulating evidence suggests that maintenance of NAD+ levels contributes to enhanced skeletal muscle function, neuroprotection, and attenuation of age-associated physiological decline.

CJC-1295 DAC is a synthetic peptide designed as an analog of growth hormone–releasing hormone (GHRH). Its primary purpose is to stimulate the pituitary gland to release more growth hormone, which subsequently elevates levels of IGF-1 (insulin-like growth factor 1). What sets the DAC version apart from the non-DAC form is the addition of a “Drug Affinity Complex.” This chemical modification allows CJC-1295 DAC to bind to albumin in the bloodstream, extending its half-life from just minutes to several days. Because of this extended duration, a single administration can keep growth hormone levels elevated for nearly a week, making it significantly more efficient in terms of dosing frequency compared to its short-lived counterpart. In research contexts, CJC-1295 DAC has been studied for its potential to promote tissue repair, support lean muscle growth, improve fat metabolism, enhance sleep quality, and contribute to overall cellular rejuvenation. These effects are largely connected to the consistent elevation of growth hormone and IGF-1, which play central roles in recovery, metabolism, and anti-aging pathways. Despite these promising avenues, CJC-1295 DAC remains a research chemical rather than an approved therapeutic drug. Human studies are limited, and while side effects observed have included injection site reactions, water retention, flushing, and tingling, the long-term implications are not yet fully understood. Because of this, its use outside of supervised research carries risks, and it is not approved by regulatory authorities for medical treatment.